Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This thing is going to explode past .20 into the close watch. Only retail on the ask.
Good morning all, or the few people that know about this Gem. Should be some fireworks today. Its primed and ready for the explosion we have all been waiting for.
$NBIO should be on all radars.
$NBIO is worth a look here fellas. Trading very healthy. About to pop to a buck.
NBIO straight up on its way to $1
$NBIO Exploding, moves on air.
$NBIO doing its thing, its time. Great news today.
$NBIO wow, now this has potential, small float, no market cap, big volume alert, and the news to drive it to $1. Just trade it, don't fall in love.
$NBIO Finally got the event to drive the volume. Worth a look.
$NBIO volume alert. Nice news today. Just what the stock needed could be the beginning of an epic climb.
$NBIO exploding on big volume.
$NBIO insiders acquiring ahead of FDA and clinical trial results. 5,600,000 FLOAT.
http://archive.fast-edgar.com//20190606/AMZ2R22CZ22FA9N3222D2ZZ2QR5VPZ27Z2B2/
Nascent Executive Vice President of Business Development Brandon Price stated, “My strong belief in the Company, and the clinical value of our Pritumumab treatment for brain cancer, compel me to further take a position in its future and help advance our asset.”
Nascent CFO Lowell Holden stated, “I believe the Company has continued to be undervalued and is now positioned to add significant value. The IND clearance by the FDA, along with the pending commencement of clinical trials, gives me confidence in its growth.
Nascent CEO Sean Carrick added, “The confidence in the Company by the management team, with their dedication and financial support, should positively impact our shareholders and the market as we continue our effort to monetize Nascent’s assets.”
$NBIO 5,600,000 float, FDA news pending.
Nascent Executive Vice President of Business Development Brandon Price stated, “My strong belief in the Company, and the clinical value of our Pritumumab treatment for brain cancer, compel me to further take a position in its future and help advance our asset.”
Nascent CFO Lowell Holden stated, “I believe the Company has continued to be undervalued and is now positioned to add significant value. The IND clearance by the FDA, along with the pending commencement of clinical trials, gives me confidence in its growth.
Nascent CEO Sean Carrick added, “The confidence in the Company by the management team, with their dedication and financial support, should positively impact our shareholders and the market as we continue our effort to monetize Nascent’s assets.”
$NBIO Insiders buying acquiring shares ahead of FDA, and clinical trial results.
5,600,000 float
http://archive.fast-edgar.com//20190606/AMZ2R22CZ22FA9N3222D2ZZ2QR5VPZ27Z2B2/
Nascent Executive Vice President of Business Development Brandon Price stated, “My strong belief in the Company, and the clinical value of our Pritumumab treatment for brain cancer, compel me to further take a position in its future and help advance our asset.”
Nascent CFO Lowell Holden stated, “I believe the Company has continued to be undervalued and is now positioned to add significant value. The IND clearance by the FDA, along with the pending commencement of clinical trials, gives me confidence in its growth.
Nascent CEO Sean Carrick added, “The confidence in the Company by the management team, with their dedication and financial support, should positively impact our shareholders and the market as we continue our effort to monetize Nascent’s assets.”
$NBIO Insiders acquiring shares ahead of FDA, and clinical trial results. BUY BUY BUY
5,600,000 float
http://archive.fast-edgar.com//20190606/AMZ2R22CZ22FA9N3222D2ZZ2QR5VPZ27Z2B2/
$NBIO Insiders buying acquiring shares ahead of FDA, and clinical trial results. BUY BUY BUY
5,600,000 float
http://archive.fast-edgar.com//20190606/AMZ2R22CZ22FA9N3222D2ZZ2QR5VPZ27Z2B2/
$NBIO Insiders acquiring shares, someone believes in the clinical trials.
http://archive.fast-edgar.com//20190606/AMZ2R22CZ22FA9N3222D2ZZ2QR5VPZ27Z2B2/
$NBIO Insiders acquiring shares.
http://archive.fast-edgar.com//20190606/AMZ2R22CZ22FA9N3222D2ZZ2QR5VPZ27Z2B2/
Great news yesterday. A move and FDA news is coming.
https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-Officers-Convert-Liability-to-Stock-in-the-Company?id=230662
$NBIO low floater, with FDA news coming....Foreshadowing below.
https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-Officers-Convert-Liability-to-Stock-in-the-Company?id=230662
$NBIO low floater, with FDA news coming....Foreshadowing below.
https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-Officers-Convert-Liability-to-Stock-in-the-Company?id=230662
$NBIO FDA news is coming, read below.
https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-Officers-Convert-Liability-to-Stock-in-the-Company?id=230662
$NBIO FDA news is coming, read below.
https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-Officers-Convert-Liability-to-Stock-in-the-Company?id=230662
$NBIO Foreshadowing, big news is coming.
https://www.otcmarkets.com/stock/NBIO/news/Nascent-Biotech-Officers-Convert-Liability-to-Stock-in-the-Company?id=230662
$NBIO Low floater about to run, do the research, we have a winner.
Keep an eye on $NBIO, low floater, about to pop. Have a powerful day fellas!!!
Keep an eye on $NBIO, low floater, about to pop. Have a powerful day fellas!!!
Pounding the table on $NBIO, low floater, about to pop. Have a powerful day fellas!!!